Cargando…

Escaping KRAS: Gaining Autonomy and Resistance to KRAS Inhibition in KRAS Mutant Cancers

SIMPLE SUMMARY: While KRAS is a driver oncogene, tumor cells can acquire mutant KRAS independency by activating pathways that functionally substitute for mutant KRAS. These KRAS-independent tumor cells exhibit a mesenchymal phenotype, readily primed for potential metastasis. The activation of YAP an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Adachi, Yuta, Kimura, Ryo, Hirade, Kentaro, Ebi, Hiromichi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8533927/ https://www.ncbi.nlm.nih.gov/pubmed/34680229 http://dx.doi.org/10.3390/cancers13205081

Ejemplares similares

Key roles of EMT for adaptive resistance to MEK inhibitor in KRAS mutant lung cancer
por: Kitai, Hidenori, et al.
Publicado: (2016)

KRAS-Dependency in Pancreatic Ductal Adenocarcinoma: Mechanisms of Escaping in Resistance to KRAS Inhibitors and Perspectives of Therapy
por: Gurreri, Enrico, et al.
Publicado: (2023)

Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
por: Xu, Ke, et al.
Publicado: (2019)

Suppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCK
por: Wang, Jieqiong, et al.
Publicado: (2016)

Correction to: Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
por: Xu, Ke, et al.
Publicado: (2020)

Not just gRASping at flaws: Finding vulnerabilities to develop novel therapies for treating KRAS mutant cancers
por: Ebi, Hiromichi, et al.
Publicado: (2014)

A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS
por: Pang, Xiufeng, et al.
Publicado: (2016)

A potent KRAS macromolecule degrader specifically targeting tumours with mutant KRAS
por: Bery, Nicolas, et al.
Publicado: (2020)

Acquired palbociclib resistance in KRAS-mutant lung cancer
por: Sherr, Charles J.
Publicado: (2018)

MUC1-C confers EMT and KRAS independence in mutant KRAS lung cancer cells
por: Kharbanda, Akriti, et al.
Publicado: (2014)

Targeting Mutant KRAS in Pancreatic Cancer: Futile or Promising?
por: Nollmann, Friederike Inga, et al.
Publicado: (2020)

Exploiting macropinocytosis for drug delivery into KRAS mutant cancer
por: Liu, Huiqin, et al.
Publicado: (2022)

Targeting KRAS mutant cancers: from druggable therapy to drug resistance
por: Zhu, Chunxiao, et al.
Publicado: (2022)

Wild-Type KRAS Allele Effects on Druggable Targets in KRAS Mutant Lung Adenocarcinomas
por: Baldelli, Elisa, et al.
Publicado: (2021)

Defeat mutant KRAS with synthetic lethality
por: Pang, Xiufeng, et al.
Publicado: (2016)

Current therapy of KRAS-mutant lung cancer
por: Ghimessy, Aron, et al.
Publicado: (2020)

Small molecular inhibitors for KRAS-mutant cancers
por: Wu, Xuan, et al.
Publicado: (2023)

KRAS Mutant Pancreatic Cancer: No Lone Path to an Effective Treatment
por: Zeitouni, Daniel, et al.
Publicado: (2016)

Targeting KRAS mutant lung cancer: light at the end of the tunnel
por: Drosten, Matthias, et al.
Publicado: (2022)

Biological significance of KRAS mutant allele expression in ovarian endometriosis
por: Yachida, Nozomi, et al.
Publicado: (2021)

Targeting KRAS in Pancreatic Cancer
por: Cowzer, Darren, et al.
Publicado: (2022)

Oncogenic KRAS: Signaling and Drug Resistance
por: Kim, Hyeon Jin, et al.
Publicado: (2021)

Dual inhibition of VEGF and PARP suppresses KRAS-mutant colorectal cancer
por: Zhong, Longhui, et al.
Publicado: (2020)

Dysregulation of KRAS signaling in pancreatic cancer is not associated with KRAS mutations and outcome
por: Lemstrova, Radmila, et al.
Publicado: (2017)

Prospective identification of resistance mechanisms to HSP90 inhibition in KRAS mutant cancer cells
por: Rouhi, Arefeh, et al.
Publicado: (2016)

KRAS mutant colorectal tumors: Past and present
por: Brand, Toni M., et al.
Publicado: (2012)

Distinct metabolic preference of atypical KRAS mutant
por: Cheong, Heesun
Publicado: (2020)

Resistance to immune checkpoint inhibitors in KRAS-mutant non-small cell lung cancer
por: Li, Yunchang, et al.
Publicado: (2022)

Oxaliplatin-Based Chemotherapy Is More Beneficial in KRAS Mutant than in KRAS Wild-Type Metastatic Colorectal Cancer Patients
por: Lin, Yu-Lin, et al.
Publicado: (2014)

Concurrent Targeting of KRAS and AKT by MiR-4689 Is a Novel Treatment Against Mutant KRAS Colorectal Cancer
por: Hiraki, Masayuki, et al.
Publicado: (2015)

Treating KRAS-mutant NSCLC: latest evidence and clinical consequences
por: Garrido, Pilar, et al.
Publicado: (2017)

Targeting the Tumor Microenvironment: An Unexplored Strategy for Mutant KRAS Tumors
por: Dias Carvalho, Patrícia, et al.
Publicado: (2019)

Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants
por: Hofmann, Marco H., et al.
Publicado: (2022)

Kras mutations increase telomerase activity and targeting telomerase is a promising therapeutic strategy for Kras-mutant NSCLC
por: Liu, Weiran, et al.
Publicado: (2016)

Targeting KRAS in Solid Tumors: Current Challenges and Future Opportunities of Novel KRAS Inhibitors
por: Indini, Alice, et al.
Publicado: (2021)

The genetics and biology of KRAS in lung cancer
por: Westcott, Peter M. K., et al.
Publicado: (2013)

Targeting the untargetable KRAS in cancer therapy
por: Liu, Pingyu, et al.
Publicado: (2019)

Therapeutic Targets of KRAS in Colorectal Cancer
por: Rahman, Shafia, et al.
Publicado: (2021)

Selective targeting of KRAS-Mutant cells by miR-126 through repression of multiple genes essential for the survival of KRAS-Mutant cells
por: Hara, Toshifumi, et al.
Publicado: (2014)

KRAS mutant allele-specific expression knockdown in pancreatic cancer model with systemically delivered bi-shRNA KRAS lipoplex
por: Rao, Donald D., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_o6vukeltkq6is5fdctdellchkg